Table 1.
Methods for monitoring anthracycline-induced cardiotoxicity.
| Methods | Diagnostic Criteria | Superiority | Inferiority |
|---|---|---|---|
| ECG [56,57,58] | 1. ST segment change 2. QT prolongation |
Accessible and economical | Insufficient specificity |
| Echocardiography | 1. A decrease in LVEF of >10% and LVEF < 50% [59,60] 2. A decrease of GLS > 15% [61,62,63,64] |
Provides information about structure and function | Unable to identify subclinical cardiomyocyte structural alterations |
| Biomarkers [65,66,67] | 1. Continuous cTnI elevation 2. BNP elevation |
Sensitive and repeatable | Insufficient evidence |
| CMRI [68,69] | A decrease in LVEF of >10% and LVEF < 50% | 1. Presents comprehensive information encompassing both the structure and function 2. Excellent repeatability |
Expensive and stringent adherence prerequisites |
| RV [70] | A decrease in LVEF of >10% and LVEF < 50% | Surpasses standard two-dimensional echocardiography in terms of precision and reproducibility when measuring LVEF | Radiation exposure |